|
1
|
Huang DH, Wang GY, Zhang JW, Li Y, Zeng XC
and Jiang N: MiR-501-5p regulates CYLD expression and promotes cell
proliferation in human hepatocellular carcinoma. Jpn J Clin Oncol.
45:738–744. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lu Y, Yue X, Cui Y, Zhang J and Wang K:
MicroRNA-124 suppresses growth of human hepatocellular carcinoma by
targeting STAT3. Biochem Biophys Res Commun. 441:873–879. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Otsuka M, Kishikawa T, Yoshikawa T,
Yamagami M, Ohno M, Takata A, Shibata C, Ishibashi R and Koike K:
MicroRNAs and liver disease. J Hum Genet. 62:75–80. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Huang Y, Shen XJ, Zou Q, Wang SP, Tang SM
and Zhang GZ: Biological functions of microRNAs: A review. J
Physiol Biochem. 67:129–139. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bosch FX, Ribes J, Diaz M and Cleries R:
Primary liver cancer: Worldwide incidence and trends.
Gastroenterology. 127 5 Suppl 1:S5–S16. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sherman M: Hepatocellular carcinoma:
Epidemiology, surveillance, and diagnosis. Semin Liver Dis.
30:3–16. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shangguan H, Tan SY and Zhang JR:
Bioinformatics analysis of gene expression profiles in
hepatocellular carcinoma. Eur Rev Med Pharmacol Sci. 19:2054–2061.
2015.PubMed/NCBI
|
|
9
|
Huang S and He X: The role of microRNAs in
liver cancer progression. Br J Cancer. 104:235–240. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lang Q and Ling C: MiR-124 suppresses cell
proliferation in hepatocellular carcinoma by targeting PIK3CA.
Biochem Biophys Res Commun. 426:247–252. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Furuta M, Kozaki KI, Tanaka S, Arii S,
Imoto I and Inazawa J: miR-124 and miR-203 are epigenetically
silenced tumor-suppressive microRNAs in hepatocellular carcinoma.
Carcinogenesis. 31:766–776. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
World Health Organization (WHO), . WHO
Handbook for Reporting Results of Cancer Treatment. WHO; Geneva:
1979
|
|
13
|
Rong M, He R, Dang Y and Chen G:
Expression and clinicopathological significance of miR-146a in
hepatocellular carcinoma tissues. Ups J Med Sci. 119:19–24. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rong M, Chen G and Dang Y: Increased
miR-221 expression in hepatocellular carcinoma tissues and its role
in enhancing cell growth and inhibiting apoptosis in vitro. BMC
Cancer. 13:212013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen G, Umelo IA, Lv S, Teugels E, Fostier
K, Kronenberger P, Dewaele A, Sadones J, Geers C and De Grève J:
miR-146a inhibits cell growth, cell migration and induces apoptosis
in non-small cell lung cancer cells. PLoS One. 8:e603172013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liu Y, Ren F, Luo Y, Rong M, Chen G and
Dang Y: Down-regulation of miR-193a-3p dictates deterioration of
HCC: A clinical real-time qRT-PCR study. Med Sci Monit.
21:2352–2360. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Egger M, Smith GD and Altman DG:
Systematic Reviews in Health Care. Meta-analysis in Context. 2nd.
BMJ Publishing Group; London: 2001, View Article : Google Scholar
|
|
19
|
Murakami Y, Kubo S, Tamori A, Itami S,
Kawamura E, Iwaisako K, Ikeda K, Kawada N, Ochiya T and Taguchi YH:
Comprehensive analysis of transcriptome and metabolome analysis in
Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma. Sci
Rep. 5:162942015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Diaz G, Melis M, Tice A, Kleiner DE,
Mishra L, Zamboni F and Farci P: Identification of microRNAs
specifically expressed in hepatitis C virus-associated
hepatocellular carcinoma. Int J Cancer. 133:816–824. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sato F, Hatano E, Kitamura K, Myomoto A,
Fujiwara T, Takizawa S, Tsuchiya S, Tsujimoto G, Uemoto S and
Shimizu K: MicroRNA profile predicts recurrence after resection in
patients with hepatocellular carcinoma within the Milan criteria.
PLoS One. 6:e164352011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
He XX, Chang Y, Meng FY, Wang MY, Xie QH,
Tang F, Li PY, Song YH and Lin JS: MicroRNA-375 targets AEG-1 in
hepatocellular carcinoma and suppresses liver cancer cell growth in
vitro and in vivo. Oncogene. 31:3357–3369. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Su H, Yang JR, Xu T, Huang J, Xu L, Yuan Y
and Zhuang SM: MicroRNA-101, down-regulated in hepatocellular
carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer
Res. 69:1135–1142. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang PR, Xu M, Toffanin S, Li Y, Llovet JM
and Russell DW: Induction of hepatocellular carcinoma by in vivo
gene targeting. Proc Natl Acad Sci USA. 109:pp. 11264–11269. 2012;
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang X and Wang X: Systematic
identification of microRNA functions by combining target prediction
and expression profiling. Nucleic Acids Res. 34:1646–1652. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dweep H and Gretz N: miRWalk2.0: A
comprehensive atlas of microRNA-target interactions. Nat Methods.
12:6972015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chang EK, Yu CY, Clarke R, Hackbarth A,
Sanders T, Esrailian E, Hommes DW and Runyon BA: Defining a patient
population with cirrhosis: An automated algorithm with natural
language processing. J Clin Gastroenterol. 50:889–894. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Alsawas M, Alahdab F, Asi N, Li DC, Wang Z
and Murad MH: Natural language processing: Use in EBM and a guide
for appraisal. Evid Based Med. 21:136–138. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang X, Tang W, Chen G, Ren F, Liang H,
Dang Y and Rong M: An encapsulation of gene signatures for
hepatocellular carcinoma, microRNA-132 predicted target genes and
the corresponding overlaps. PLoS One. 11:e01594982016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Huang WT, Wang HL, Yang H, Ren FH, Luo YH,
Huang CQ, Liang YY, Liang HW, Chen G and Dang YW: Lower expressed
miR-198 and its potential targets in hepatocellular carcinoma: A
clinicopathological and in silico study. Onco Targets Ther.
9:5163–5180. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liese J, Peveling-Oberhag J, Doering C,
Schnitzbauer AA, Herrmann E, Zangos S, Hansmann ML, Moench C,
Welker MW, Zeuzem S, et al: A possible role of microRNAs as
predictive markers for the recurrence of hepatocellular carcinoma
after liver transplantation. Transpl Int. 29:369–380. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ito K and Murphy D: Application of ggplot2
to Pharmacometric Graphics. CPT Pharmacometrics Syst Pharmacol.
2:e792013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Xu C, Zeng Q, Xu W, Jiao L, Chen Y, Zhang
Z, Wu C, Jin T, Pan A, Wei R, et al: miRNA-100 inhibits human
bladder urothelial carcinogenesis by directly targeting mTOR. Mol
Cancer Ther. 12:207–219. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ma Y, Han W, Yang L, He L and Wang H: The
regulation of miRNAs in inflammation-related carcinogenesis. Curr
Pharm Des. 21:3023–3031. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wan X, Ding X, Chen S, Song H, Jiang H,
Fang Y, Li P and Guo J: The functional sites of miRNAs and lncRNAs
in gastric carcinogenesis. Tumour Biol. 36:521–532. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Xu L, Dai W, Li J, He LI, Wang F, Xia Y,
Chen K, Li S, Liu T, Lu J, et al: Methylation-regulated miR-124-1
suppresses tumorigenesis in hepatocellular carcinoma by targeting
CASC3. Oncotarget. 7:26027–26041. 2016.PubMed/NCBI
|
|
37
|
Zheng F, Liao YJ, Cai MY, Liu YH, Liu TH,
Chen SP, Bian XW, Guan XY, Lin MC, Zeng YX, et al: The putative
tumour suppressor microRNA-124 modulates hepatocellular carcinoma
cell aggressiveness by repressing ROCK2 and EZH2. Gut. 61:278–289.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Shi XB, Xue L, Ma AH, Tepper CG,
Gandour-Edwards R, Kung HJ and deVere White RW: Tumor suppressive
miR-124 targets androgen receptor and inhibits proliferation of
prostate cancer cells. Oncogene. 32:4130–4138. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lv XB, Jiao Y, Qing Y, Hu H, Cui X, Lin T,
Song E and Yu F: miR-124 suppresses multiple steps of breast cancer
metastasis by targeting a cohort of pro-metastatic genes in vitro.
Chin J Cancer. 30:821–830. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Li H, Xie S, Liu M, Chen Z, Liu X, Wang L,
Li D and Zhou Y: The clinical significance of downregulation of
mir-124-3p, mir-146a-5p, mir-155-5p and mir-335-5p in gastric
cancer tumorigenesis. Int J Oncol. 45:197–208. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wang P, Chen L, Zhang J, Chen H, Fan J,
Wang K, Luo J, Chen Z, Meng Z and Liu L: Methylation-mediated
silencing of the miR-124 genes facilitates pancreatic cancer
progression and metastasis by targeting Rac1. Oncogene. 33:514–524.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhao W, Cheng Y, Zhang C, You Q, Shen X,
Guo W and Jiao Y: Genome-wide identification and characterization
of circular RNAs by high throughput sequencing in soybean. Sci Rep.
7:56362017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Becker HF, Heliou A, Djaout K, Lestini R,
Regnier M and Myllykallio H: High-throughput sequencing reveals
circular substrates for an archaeal RNA ligase. RNA Biology.
14:1075–1085. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Nair AA, Niu N, Tang X, Thompson KJ, Wang
L, Kocher JP, Subramanian S and Kalari KR: Circular RNAs and their
associations with breast cancer subtypes. Oncotarget.
7:80967–80979. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Wang X, Zhang Y, Huang L, Zhang J, Pan F,
Li B, Yan Y, Jia B, Liu H, Li S and Zheng W: Decreased expression
of hsa_circ_001988 in colorectal cancer and its clinical
significances. Int J Clin Exp Pathol. 8:16020–16025.
2015.PubMed/NCBI
|
|
46
|
Li P, Chen S, Chen H, Mo X, Li T, Shao Y,
Xiao B and Guo J: Using circular RNA as a novel type of biomarker
in the screening of gastric cancer. Clin Chim Acta. 444:132–136.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Shang X, Li G, Liu H, Li T, Liu J, Zhao Q
and Wang C: Comprehensive circular RNA profiling reveals that
hsa_circ_0005075, a new circular RNA biomarker, is involved in
hepatocellular crcinoma development. Medicine (Baltimore).
95:e38112016. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Qin M, Liu G, Huo X, Tao X, Sun X, Ge Z,
Yang J, Fan J, Liu L and Qin W: Hsa_circ_0001649: A circular RNA
and potential novel biomarker for hepatocellular carcinoma. Cancer
Biomark. 16:161–169. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Xu L, Zhang M, Zheng X, Yi P, Lan C and Xu
M: The circular RNA ciRS-7 (Cdr1as) acts as a risk factor of
hepatic microvascular invasion in hepatocellular carcinoma. J
Cancer Res Clin Oncol. 143:17–27. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Zheng Q, Bao C, Guo W, Li S, Chen J, Chen
B, Luo Y, Lyu D, Li Y, Shi G, et al: Circular RNA profiling reveals
an abundant circHIPK3 that regulates cell growth by sponging
multiple miRNAs. Nat Commun. 7:112152016. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Gong XL and Qin SK: Progress in systemic
therapy of advanced hepatocellular carcinoma. World J
Gastroenterol. 22:6582–6594. 2016. View Article : Google Scholar : PubMed/NCBI
|
